Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2021-05-01

Summary

This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.

• Phase: Phase 2

Details

• Lead Sponsor: Northwestern University
• Collaborators: Robert H. Lurie Cancer Center; Seagen Inc.; Seattle Genetics, Inc.
• Treatments: Antibodies; Antibodies, Monoclonal; Brentuximab Vedotin; Dacarbazine; Doxorubicin; Fluorodeoxyglucose F18; Immunoconjugates; Immunoglobulins; Liposomal doxorubicin; Vinblastine